Table 1: Tumour-associated markers predicting BCG treatment outcome. The markers are ordered from the most studied to the less, and, within each marker, the studies are ordered by quality score.

Marker AuthorQualityn Treatment schemeImpactOutcome
Rec(P)RFS
(P/HR (95% CI))
Prog(P)PFS
(P/HR (95% CI))

p53
Lopez-Beltran et al., [34]8/851iBCGX0.0332/NS*X0.0041/1.003 (1.002–1.074)
Park et al., [26]7/861iBCGNSNSX0.0495
Zlotta et al., [22]7/847iBCGNoneNSNS/NS*NSNS/NS*
Lee et al., [35]7/832iBCGX0.0027/3.8 (1.3–11.4)*XX
Lacombe et al., [18]7/898iBCGNSXX0.0001/2.5 (1.1–5.5)*
Palou et al., [31]6/892iBCG<PFS-MNSNSXNS/0.018*
Esuvaranathan et al., [30]6/880iBCGNoneNSNSXNS
Kyroudi-Voulgari et al., [27]6/866iBCGNoneNSXXX
Cormio et al., [32]5/827mBCGNSNSNS0.06
Saint et al., [23]5/8102iBCG/mBCGNS0.03/0.15 (0.06–0.42)*0.001<0.0001
Peyromaure et al., [24]5/829iBCGNoneNSNSNSNS
Caliskan and Türkeri [19]5/830iBCG>ProgNS/NS XNS/NS 0.04
Pages et al., [25]4/843iBCGNoneNSNSXX
Okamura et al., [20]4/838mBCGNoneNSXXX
Moyano Calvo et al., [29]3/851iBCGNoneNSXXX
Moyano Calvoet al., [33]3/871iBCGNoneNSXNSX
Lebret et al., [21]3/835iBCGNoneNSXXX
Serdar et al., [28]1/824iBCGNoneNSNSXX

Ki-67
Lopez-Beltran et al., [34]8/851iBCGX0.0034/NS*X0.0163/NS*
Park et al., [26]7/861iBCGNSNSXNS
 >25%Zlotta et al., [22]7/847iBCGNS0.02/NS*NSNS/NS*
Lee et al., [35]7/832iBCG0.04130.0164/NS*XX
Palou et al., [31]6/892iBCG>Rec0.015NSXNS/NS*
Kyroudi-Voulgari et al., [27]6/866iBCG<0.05XXX
Blanchet et al., [38]5/857iBCGXNS/NS*X0.0001/4.61 (P < 0.04)
 >20%Lebret et al., [37]5/825iBCG0.03XXX
Moyano Calvo et al., [33]3/871iBCGNoneNSXNSX
Moyano Calvo et al., [29]3/851iBCGNoneNSXXX
pRB
Park et al., [26]7/861iBCGNSNSXNS
 +Esuvaranathan et al., [30]6/880iBCGNoneNSNSXNS
 Altered expCormio et al., [39]5/827mBCGX0.037X0.018

CD68
 High TAMAyari et al., [41]6/846iBCG/mBCGX0.093/3.81 (1.32–11) XX
 High TAMTakayama et al., [42]6/8411iBCG0.00230.0002/1.7 (1.48–5.03)cXX
Kitamura et al., [48]4/830iBCGNoneXNS/NS*XX

c-erbB2Lee et al., [35]7/832iBCGNoneXNS/NS*XX
Janane et al., [43]5/884iBCGX<0.01XX
Morgan et al., [95]5/882iBCGNoneNSXXX

E-CadherinMoyano Calvo et al., [29]3/851iBCGNoneNSXXX
Serdar et al., [28]1/824iBCGNoneNSNSXX

bcl-2Lee et al., [35]7/832iBCGX0.0112/NS*XX
Okamura et al., [20]4/838mBCG+0.044XXX

p21Lopez-Beltran et al., [34]8/851iBCGNoneXNS/NS*XNS/NS*
 >10%Zlotta et al., [22]7/847iBCGNS0.02/NS*NSNS/NS*

p27Lopez-Beltran et al., [34]8/851iBCG+X0.0005/0.997 (0.995–0.999)*X0.0161/NS*
Park et al., [26]7/861iBCGNSNSXNS

Cyclin D1Lopez-Beltran et al., [34]8/851iBCGX0.0103/NS*X<0.0001/1.009 (1.002–1.074)*

Cyclin D3Lopez-Beltran et al., [34]8/851iBCGX0.0332/NSX0.0041/1.003 (1.002–1.074)*

PTENPark et al., [26]7/861iBCGNSNSXNS

FGFR3Park et al., [26]7/861iBCGNSNSXNS

CD9Park et al., [26]7/861iBCGNSNSXNS

hTERT
 Pre-treat  >75%Zachos, [96]7/830iBCGX0.05/NS NS/NS X

c-mycLee et al., [35]7/832iBCGNoneXNS/NS*XX

Cathepsin DLee et al., [35]7/832iBCGX0.0235/NS*XX

CD83
 High
 CD83+
Ayari et al., [41]6/853mBCGX0.0001/9.81 (1.12–85.7) XX

EzrinPalou et al., [31]6/892iBCG0.0410.06X0.009/0.031*

NKp30Yutkin, [46]6/817iBCG<Rec0.0026XXX

NKp44Yutkin, [46]6/817iBCG<Rec0.027XXX

NKp46Yutkin, [46]6/817iBCG<Rec0.044XXX
PD-L1Inman et al., [97]5/844iBCG/mBCGNoneNSXXX

CD25Honda et al., [98]5/816iBCGNoneNSXXX

Cox-2Kim et al., [45]5/837iBCGX0.0493X0.0272

VEGFMorgan et al., [95]5/882iBCGNoneNSXXX

TCR Honda et al., [98]5/816iBCGNoneNSXXX

HSP60Lebret et al., [47]4/833iBCGNoneNSXNSX

HSP90
 Loss expLebret et al., [47]4/833iBCG0.0001X0.0001X

CD4Kitamura et al., [48]4/830iBCGNoneXNS/NS*XX

CD8Kitamura et al., [48]4/830iBCGNoneXNS/NS*XX

HLA class IKitamura et al., [48]4/830iBCG+X0.0394/0.06 (0.01–0.4)XX

CD20Kitamura et al., [48]4/830iBCGNoneXNS/NS*XX

TIA-1Kitamura et al., [48]4/830iBCGNoneX0.0393/NS*XX

S-100Kitamura et al., [48]4/830iBCGNoneXNS/NS*XX

FOXP3Kitamura et al., [48]4/830iBCGNoneXNS/NS*XX

PCNAOkamura et al., [20]4/838mBCGNoneNSXXX

HSP65Ardelt et al., [99]3/816mBCGNoneNSXXX

B-CateninMoyano Calvo et al., [29]3/851iBCG+<0.05XXX

−: negative impact, marker associated with a poor BCG response.
+: positive impact, marker associated to a better BCG response.
Rec: recurrence; P value for recurrence.
RFS: recurrence-free survival; P value for log-rank test/HR: hazard ratio from Cox regression; (95% Cl): 95% confidence interval.
Prog: progression; P value for progression.
PFS: progression-free survival; P value for log-rank test/HR: hazard ratio from Cox regression; (95% Cl): 95% confidence interval.
iBCG: induction BCG scheme only.
mBCG: maintenance BCG scheme.
NS: no statistical significance.
X: not evaluated.
*all analysed variables (independent prognostic factor).
adjusted for grade and stage.
adjusted for age, gender, T stage and number of mBCG instillations.
adjusted for age and gender.
adjusted for age, gender, T stage.
1only CIS patients.